Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxybate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.67 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 5/20 | 0.41 |
| ▸ | PPARD | Q03181 | 5/20 | 0.41 |
| ▸ | PPARA | Q07869 | 5/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | FABP4 | P15090 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lactic Acid SCHEMBL5709392 | 0.93 | GPR84 (0.65) | CAMK2AGPR84FFAR1FFAR4TP53 | |
| 1,6-Hexanediol SCHEMBL3482818 | 0.91 | GPR84 (0.70) | CAMK2AGPR84FFAR1FFAR4TP53 | |
| Lactic Acid SCHEMBL3038365 | 0.91 | GPR84 (0.70) | CAMK2AGPR84FFAR1FFAR4TP53 | |
| Succinic Acid SCHEMBL194813 | 0.91 | GPR84 (0.54) | CAMK2AGPR84FFAR1FFAR4TP53 | |
| Glutarate SCHEMBL28852051 | 0.87 | SLC22A6 (0.61) | GPR84FFAR1FFAR4TP53LMNA | |
| Adipic Acid SCHEMBL5306019 | 0.87 | LMNA (0.61) | GPR84FFAR1FFAR4TP53LMNA | |
| 3-Hydroxybutyric Acid, (+/-)- SCHEMBL3507151 | 0.87 | CAMK2A (0.50) | CAMK2AGPR84FFAR1FFAR4TP53 | |
| Lactic Acid SCHEMBL21356987 | 0.85 | TP53 (0.58) | CAMK2AGPR84FFAR1FFAR4TP53 | |
| Oxybate SCHEMBL4314043 | 0.85 | CAMK2A (0.48) | CAMK2AGPR84FFAR1FFAR4TP53 | |
| Lactic Acid SCHEMBL8850880 | 0.85 | TP53 (0.65) | CAMK2AGPR84FFAR1FFAR4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377994-B2 | Use of the reductive glycine pathway for generating formatotrophic and autotrophic microorganisms | Yeda Research and Developmetn Co. Ltd. (IL) | 2019-08-13 | — | — | US | disclosed |
| US-20190032027-A1 | USE OF THE REDUCTIVE GLYCINE PATHWAY FOR GENERATING FORMATOTROPHIC AND AUTOTROPHIC MICROORGANISMS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2019-01-31 | — | — | US | disclosed |
| US-10155933-B2 | Use of the reductive glycine pathway for generating formatotrophic and autotrophic microorganisms | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2018-12-18 | — | — | US | disclosed |
| US-20150218528-A1 | USE OF THE REDUCTIVE GLYCINE PATHWAY FOR GENERATING FORMATOTROPHIC AND AUTOTROPHIC MICROORGANISMS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-08-06 | — | — | US | disclosed |
| US-20110098301-A1 | Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders | BAYER HEALTHCARE LLC (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2084209-A1 | COPOLYMER COMPRISING 4-HYDROXYBUTYRATE UNIT AND LACTATE UNIT AND ITS MANUFACTURING METHOD | LG Chem, Ltd. (KR) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008062995-A1 | COPOLYMER COMPRISING 4-HYDROXYBUTYRATE UNIT AND LACTATE UNIT AND ITS MANUFACTURING METHOD | LG CHEM, LTD. (KR) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098301-A1 | Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders | DPYD, TYMP, TYMS | CAMK2A 4208/4885GPR84 3905/4885FFAR1 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.